Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update

Inhibrx, Inc. (NASDAQ:INBX) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 955,400 shares, a decrease of 19.7% from the February 28th total of 1,190,000 shares. Based on an average daily trading volume, of 91,300 shares, the days-to-cover ratio is currently 10.5 days. Approximately 9.6% of the shares of the stock are short sold.

Inhibrx Stock Performance

Shares of INBX traded up $0.06 during mid-day trading on Tuesday, hitting $14.05. The company’s stock had a trading volume of 201,067 shares, compared to its average volume of 217,794. The firm has a 50-day moving average price of $13.37 and a 200 day moving average price of $14.59. Inhibrx has a fifty-two week low of $10.80 and a fifty-two week high of $35.42.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The firm had revenue of $0.10 million during the quarter. Equities research analysts anticipate that Inhibrx will post 104.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Institutional Investors Weigh In On Inhibrx

Hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. purchased a new position in Inhibrx in the 4th quarter worth about $28,000. Natixis purchased a new stake in Inhibrx during the fourth quarter valued at about $31,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Inhibrx in the fourth quarter worth about $47,000. New York State Common Retirement Fund acquired a new stake in shares of Inhibrx during the fourth quarter valued at approximately $53,000. Finally, State of Wyoming acquired a new stake in Inhibrx during the 4th quarter valued at $83,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.